Prevalence and risk factors for biopsy‐proven non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones

Abstract

Prevalence of NASH among patients with gallstones is lower than estimated previously, but NASH is frequent particularly in those patients with concurrent metabolic syndrome. The combination of an increased HOMA score with fatty liver on ultrasound has a good accuracy for predicting NASH in patients with gallstones.

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

“…A postmortem study conducted in Greece on 498 cases of ischaemic heart disease or traffic accident deaths revealed simple steatosis in 31.3% and NASH in 39.8% of individuals 39 . In a study of Spanish patients with gallstone disease scheduled for cholecystectomy, 51.6% of them had histological evidence of NAFLD and 19.8% of NASH 40 . Of note, in this cohort, ultrasono graphy confirmed a fatty liver in only 67.6% of the histo logically diagnosed patients with NAFLD.…”

Ideal cardiovascular health metrics and the risk of non‐alcoholic fatty liver disease: A cross‐sectional study in northern China

“…Non‐alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases . The prevalence of NAFLD is up to 50% in the general population . In China, the prevalence of NAFLD ranges from 6.0% to 27.0%, accounting for nearly half of the total cases worldwide .…”

Research update for articles published in EJCI in 2014

“…While in the last 2 years the key role of hepatocyte-specific CD36 expression in the development of fatty liver, by modulating the rate of free fatty acids uptake in hepatocytes [12,13] as well as the significance of sCD36 as prognostic biomarker for diabetic nephropathy [14] have been reinforced, no new evidence exists so far on the value of sCD36 as noninvasive biomarker of advanced steatosis in NAFLD. We propose that measurement of circulating sCD36, alone or in combination with other risk factors we have recently reported [15], is useful to identify those NAFLD patients with higher degrees of steatosis. This hypothesis, however, must be validated in large cohorts of patients with biopsy-proven NAFLD.…”